Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

B1160000

Bupivacaine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H28N2O · HCl
CAS Number:
18010-40-7
Molecular Weight:
324.89
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

bupivacaine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H

InChI key

SIEYLFHKZGLBNX-UHFFFAOYSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Bupivacaine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1078507

Bupivacaine hydrochloride, United States Pharmacopeia (USP) Reference Standard

Y0000088

Bupivacaine impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000089

Bupivacaine impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001575

Bupivacaine impurity F, European Pharmacopoeia (EP) Reference Standard

1078529

Bupivacaine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1078518

Bupivacaine Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1738

Bupivacaine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1756

Bupivacaine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

BP479

Bupivacaine hydrochloride, British Pharmacopoeia (BP) Reference Standard

PHR9084

(S)-Bupivacaine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9147

N-(2,6-Dimethylphenyl)pyridine-2-carboxamide, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H300 + H310 + H330

Hazard Classifications

Acute Tox. 1 Inhalation - Acute Tox. 2 Dermal - Acute Tox. 2 Oral

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

B1160000-1EA:
B1160000:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

David R Walega et al.
Journal of oral & facial pain and headache, 28(2), 171-175 (2014-05-14)
Burning Mouth Syndrome (BMS) is a chronic painful disorder characterized by unremitting bilateral burning oral pain often associated with taste abnormalities and complaints of dry mouth. The diagnosis is made by history and symptom presentation in the absence of an
David Buck et al.
Anesthesia and analgesia, 119(1), 137-140 (2014-06-20)
An otherwise healthy 11-month-old, 8-kg infant presented for an elective circumcision. After a penile block with an excessive dose of 0.5% bupivacaine, the patient progressed to ventricular tachycardia. He was resuscitated with intralipid and had an uneventful recovery. The case
Michael J Beebe et al.
Clinical orthopaedics and related research, 472(5), 1394-1399 (2013-07-17)
Continuous femoral nerve block has been shown to decrease opioid use, improve postoperative pain scores, and decrease length of stay. However, several studies have raised the concern that continuous femoral nerve block may delay patient ambulation and increase the risk
Mingquan Chen et al.
Anesthesia and analgesia, 118(4), 863-868 (2014-03-22)
In this study, we sought to determine the median effective dose (ED50) for motor block of intrathecally administered plain bupivacaine in adults (20-80 years) and to assess the effect of age on ED50 required for motor block. This study was
Michael R Fettiplace et al.
Anesthesiology, 120(4), 915-925 (2014-02-06)
Recent publications have questioned the validity of the "lipid sink" theory of lipid resuscitation while others have identified sink-independent effects and posed alternative mechanisms such as hemodilution. To address these issues, the authors tested the dose-dependent response to intravenous lipid
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service